2024-06-28 04:35:42 pm | Source: Reuters
India plans incentives for diabetes, obesity drug makers in 2026, government official says
India is planning to offer incentives to promote local manufacturing of GLP-1 drugs used to treat diabetes and obesity, in 2026, a top government official said on Friday.
GLP-1 drugs, originally approved to treat diabetes, are also widely being used to treat obesity as they slow digestion, helping patients feel full longer.
Danish drugmaker Novo Nordisk's patent on semaglutide - a GLP-1 agonist and the key ingredient in its wildly popular obesity drug Wegovy and diabetes drug Ozempic - is set to expire in India in 2026, industry experts say.
Disclaimer:
The content of this article is for informational purposes only and should not be considered financial or
investment advice. Investments in financial markets are subject to market risks, and past performance is
not indicative of future results. Readers are strongly advised to consult a licensed financial expert or
advisor for tailored advice before making any investment decisions. The data and information presented
in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the
content of this article for any current or future financial references.
To Read Complete Disclaimer Click Here
Latest News
India`s white-collar job market ends this fiscal str...
Corporate, Economic & Global Updates 07th April 2026...
India`s credit card spends grow 6 pc in February
Nifty witnessed a volatile session on Monday but end...
Indian Railways approves Rs 1,364 crore to expand Ka...
Daily Derivative Report - 07th April 2026 by Religar...
Over 18 crore LPG cylinders delivered since March 1,...
Nifty weekly OI peaks at 24000 CE and 22000 PE; mont...
Stocks struggle, oil jumps as Trump`s Iran deadline ...
The large upside aligns with steeper 24400 objective...
